University-born Startup InnoJin Inc. Completes Series C Funding, Bringing Total Raised Capital to 950 Million JPY

InnoJin Inc. (headquartered in Bunkyo-ku, Tokyo), a university-born startup, has successfully completed its Series C funding round through a third-party allotment of new shares. This brings the company’s total funding to 950 million JPY.

To date, through seed, Series A, and Series B rounds, InnoJin has built a solid foundation for the development and social implementation of medical solutions, supported by numerous partner companies and individual investors.

The newly raised funds will be used to further accelerate clinical research and trials for its in-development software-based medical devices (SaMD), aiming for early social implementation and commercialization.

Additionally, InnoJin will leverage the specialized expertise and offline medical networks of the participating investors and subscribing companies to further expand and grow its online medical services. The company aims to build a seamless healthcare delivery system integrating online and in-person care, accelerating the social adoption of its services.

InnoJin’s Strengths and Growth Strategy for In-Development Products

InnoJin operates a unique business model combining an ophthalmology-specialized online medical platform, healthcare applications, and software-based medical devices (SaMD) designed for disease diagnosis, treatment, and prevention. While comprehensive telemedicine services are expanding, digital health platforms specialized in ophthalmology remain limited. InnoJin has established a distinct position in this niche.

The company aims to build a comprehensive digital ophthalmology platform by consistently managing patient disease awareness and encouragement to seek care, delivering online consultations, and referring patients to appropriate in-person medical institutions.

Furthermore, by utilizing data accumulated through the cyclical integration of “disease awareness and encouragement,” “online consultations,” and “referrals to medical institutions,” InnoJin aims to realize a sustainable next-generation ophthalmic healthcare infrastructure that connects to preventive and personalized medicine.

With this funding, the company will advance its business with two main pillars: “expansion of the online medical platform” and “acceleration of clinical development and regulatory approval processes for the SaMD pipeline toward commercialization.”

Ophthalmology-Specialized Online Medical Platform

Smartphone penetration has reached 90.6% (Ministry of Internal Affairs and Communications, “2023 Survey on Information and Communications Usage”), and with the advancement of the digital society, the importance of supporting eye health is growing.

However, ophthalmology is a highly specialized field where physicians from other specialties cannot easily substitute for diagnosis and treatment. Additionally, specialized diagnostic equipment is required, making in-person visits the traditional norm. Yet, long waiting times at hospitals and clinics have become commonplace, making continuous visits difficult for those with work or academic commitments during daytime hours.

To address these challenges associated with in-person visits, InnoJin provides a seamless healthcare experience connecting from the initial concern about eye discomfort to treatment.

From appointment booking, consultation, diagnosis, to payment, the entire process can be completed via smartphone. Experienced ophthalmologists generally conduct the consultations. The platform supports insured ophthalmic treatments such as dry eye, styes, eye strain, and hay fever, and has established a system to ship prescribed medications on the same day, with delivery as early as the next day.

Moreover, for patients requiring detailed examinations or in-person consultations, InnoJin smoothly refers them to nearby partner ophthalmology clinics, building a medical network where online and in-person care complement each other.

Healthcare Apps and Software-Based Medical Devices (SaMD)

In the software-based medical device and therapeutic app market, projected to reach approximately 28.5 billion JPY by 2035, InnoJin is advancing the development of SaMD products targeting diseases with high unmet medical needs—from encouraging medical visits to diagnostic and therapeutic support—with the goal of sequential commercialization.

・ Smartphone-based SaMD for Hay Fever Treatment Support (Not yet approved)

Targeting hay fever, which affects over 50 million people in Japan with diverse causes, the company provides a digital intervention program that visualizes disease risk and promotes cognitive and behavioral change, supporting personalized treatment and prevention for each individual.

・ Smartphone-based SaMD for Dry Eye Diagnostic Support (Not yet approved)

Targeting dry eye, which affects approximately 20 million people in Japan and is expected to increase further due to aging and digitalization, the company is developing a programmatic medical device that enables simple diagnosis via a smartphone app.

・ VR-Based SaMD for Pediatric Amblyopia Therapy (Not yet approved)

Traditional patching therapy for amblyopia suffers from low treatment adherence and high burden on caregivers. InnoJin’s proprietary technology displays a clear image to the amblyopic eye and a blurred image to the healthy eye via VR, creating an engaging, game-like therapy environment to improve treatment adherence. Additionally, physicians can access detailed data such as therapy duration.

About InnoJin

InnoJin is a university-born startup committed to the vision of “human-friendly digital healthcare,” engaging in the research, development, regulatory approval, and commercialization of medical devices utilizing innovative digital technologies.

In 2022, the company obtained Class II medical device manufacturing and marketing approval, and is advancing R&D for products including a smartphone-based SaMD for dry eye diagnosis support, a smartphone-based SaMD for hay fever treatment support, and a VR-based SaMD for pediatric amblyopia therapy. Through the development of a digital platform for ophthalmic telemedicine, InnoJin is working to realize healthcare DX (digital transformation) in the field of ophthalmology.

Company Overview

InnoJin Inc.

Established: December 1, 2020

Headquarters: 2-14-10 Hongo, Bunkyo-ku, Tokyo

Phone: 03-6670-8993

Website: https://innojin.co.jp/

Business Activities:

・ IT-based business related to healthcare and medical services

・ Collection, analysis, and provision of healthcare and medical information

・ Planning, production, and sales of web and digital content related to healthcare and medicine

・ Consulting services related to healthcare and medicine

・ Research related to healthcare and medicine

・ Educational services

・ Planning, policy-making, and all related businesses for books, printed materials, and electronic publications prior to sales